Compare RAYA & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAYA | ENVB |
|---|---|---|
| Founded | 2019 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 3.0M |
| IPO Year | 2021 | 2000 |
| Metric | RAYA | ENVB |
|---|---|---|
| Price | $0.40 | $1.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 393.0K | 36.5K |
| Earning Date | 04-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.03 | $0.56 |
| 52 Week High | $10.14 | $13.25 |
| Indicator | RAYA | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 21.50 | 35.70 |
| Support Level | $0.04 | $1.11 |
| Resistance Level | $0.92 | $2.06 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 12.63 | 13.64 |
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.